Abbvie reported on Friday also. Androgel sales were 218 Million for the quarter which is down 15.6% on corresponding quarter for last year. It was also down 14.2% on the previous quarter (254 Million).
I recall the recent prescription data showing no significant difference in market share over the term. I'm thinking Axiron outperformance must be due to an increase in average sale price...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
-0.001(5.88%) |
Mkt cap ! $6.548M | |||
| Open | High | Low | Value | Volume |
| 1.7¢ | 1.7¢ | 1.6¢ | $1.303K | 79.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 187934 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 358041 | 1 |
View Market Depth
| Last trade - 14.24pm 07/08/2025 (20 minute delay) ? |
| ACR (ASX) Chart |